MX385216B - Prueba de diagnostico basada en fragmento de rgma. - Google Patents
Prueba de diagnostico basada en fragmento de rgma.Info
- Publication number
- MX385216B MX385216B MX2017003063A MX2017003063A MX385216B MX 385216 B MX385216 B MX 385216B MX 2017003063 A MX2017003063 A MX 2017003063A MX 2017003063 A MX2017003063 A MX 2017003063A MX 385216 B MX385216 B MX 385216B
- Authority
- MX
- Mexico
- Prior art keywords
- diagnostic test
- test based
- rgma fragment
- rgma
- drug treatment
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048745P | 2014-09-10 | 2014-09-10 | |
| PCT/EP2015/070603 WO2016038084A1 (en) | 2014-09-10 | 2015-09-09 | Rgma fragment based diagnostic assay |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017003063A MX2017003063A (es) | 2017-06-14 |
| MX385216B true MX385216B (es) | 2025-03-14 |
Family
ID=54064367
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003063A MX385216B (es) | 2014-09-10 | 2015-09-09 | Prueba de diagnostico basada en fragmento de rgma. |
| MX2021009528A MX2021009528A (es) | 2014-09-10 | 2017-03-08 | Prueba de diagnostico basada en fragmento de rgma. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009528A MX2021009528A (es) | 2014-09-10 | 2017-03-08 | Prueba de diagnostico basada en fragmento de rgma. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20160069907A1 (enExample) |
| EP (1) | EP3191847A1 (enExample) |
| JP (1) | JP6879905B2 (enExample) |
| CN (2) | CN107076757A (enExample) |
| AU (2) | AU2015314240A1 (enExample) |
| BR (1) | BR112017004883A2 (enExample) |
| CA (1) | CA2956814A1 (enExample) |
| MX (2) | MX385216B (enExample) |
| TW (2) | TW202119030A (enExample) |
| WO (1) | WO2016038084A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2632476A1 (en) * | 2005-12-05 | 2007-06-14 | Affinium Pharmaceuticals, Inc. | Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents |
| MX2012006560A (es) * | 2009-12-08 | 2012-10-05 | Abbott Gmbh & Co Kg | Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal. |
| CN116942831A (zh) | 2018-07-19 | 2023-10-27 | 国立大学法人东京大学 | Htlv-1相关性脊髓病（ham）治疗或预防剂、及ham的治疗方法 |
| CN118767130A (zh) * | 2020-01-15 | 2024-10-15 | 国立大学法人大阪大学 | 糖尿病性自主神经障碍的预防或治疗剂 |
| CN112402554B (zh) * | 2020-10-26 | 2022-03-01 | 中国中医科学院广安门医院 | 一种治疗脑白质病的中药组合物及其应用 |
| US12306192B2 (en) | 2021-02-08 | 2025-05-20 | Cedars-Sinai Medical Center | Method of detecting cognitive impairment |
| EP4374300A4 (en) * | 2021-07-23 | 2025-06-11 | Cedars-Sinai Medical Center | Methods and systems for the early detection of ocular and/or neurological conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000002053A2 (en) * | 1998-07-03 | 2000-01-13 | Innogenetics N.V. | Differential diagnosis of neurodegeneration |
| EP1355666B1 (en) | 2000-12-22 | 2012-06-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive guidance molecule (RGM) and its modulators |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| MX2012006560A (es) * | 2009-12-08 | 2012-10-05 | Abbott Gmbh & Co Kg | Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal. |
| KR102284780B1 (ko) * | 2009-12-09 | 2021-08-02 | 미쓰비시 타나베 파마 코퍼레이션 | Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법 |
| EP3252072A3 (en) * | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2012047706A2 (en) * | 2010-10-06 | 2012-04-12 | Massachusetts Eye & Ear Infirmary | Methods for promotiing reinnervation of auditory hair cells |
| EP2723866B1 (en) * | 2011-06-22 | 2018-03-28 | Universite Laval | Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease |
| PE20190907A1 (es) | 2012-01-27 | 2019-06-26 | AbbVie Deutschland GmbH and Co KG | Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas |
-
2015
- 2015-09-09 WO PCT/EP2015/070603 patent/WO2016038084A1/en not_active Ceased
- 2015-09-09 TW TW109124697A patent/TW202119030A/zh unknown
- 2015-09-09 BR BR112017004883A patent/BR112017004883A2/pt not_active IP Right Cessation
- 2015-09-09 EP EP15759819.4A patent/EP3191847A1/en not_active Withdrawn
- 2015-09-09 CN CN201580048412.5A patent/CN107076757A/zh active Pending
- 2015-09-09 TW TW104129821A patent/TW201617612A/zh unknown
- 2015-09-09 MX MX2017003063A patent/MX385216B/es unknown
- 2015-09-09 JP JP2017513509A patent/JP6879905B2/ja not_active Expired - Fee Related
- 2015-09-09 AU AU2015314240A patent/AU2015314240A1/en not_active Abandoned
- 2015-09-09 CN CN202110521844.0A patent/CN113267630A/zh active Pending
- 2015-09-09 CA CA2956814A patent/CA2956814A1/en not_active Abandoned
- 2015-09-10 US US14/850,185 patent/US20160069907A1/en not_active Abandoned
-
2017
- 2017-03-08 MX MX2021009528A patent/MX2021009528A/es unknown
-
2019
- 2019-09-04 US US16/560,632 patent/US20200241012A1/en not_active Abandoned
-
2021
- 2021-03-02 US US17/190,135 patent/US20220018855A1/en not_active Abandoned
-
2022
- 2022-01-12 AU AU2022200160A patent/AU2022200160A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN107076757A (zh) | 2017-08-18 |
| BR112017004883A2 (pt) | 2017-12-05 |
| AU2022200160A1 (en) | 2022-02-10 |
| US20160069907A1 (en) | 2016-03-10 |
| EP3191847A1 (en) | 2017-07-19 |
| US20220018855A1 (en) | 2022-01-20 |
| WO2016038084A1 (en) | 2016-03-17 |
| TW202119030A (zh) | 2021-05-16 |
| CA2956814A1 (en) | 2016-03-17 |
| US20200241012A1 (en) | 2020-07-30 |
| AU2015314240A1 (en) | 2017-02-09 |
| CN113267630A (zh) | 2021-08-17 |
| MX2021009528A (es) | 2021-09-08 |
| JP6879905B2 (ja) | 2021-06-02 |
| JP2017526930A (ja) | 2017-09-14 |
| MX2017003063A (es) | 2017-06-14 |
| TW201617612A (zh) | 2016-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX385216B (es) | Prueba de diagnostico basada en fragmento de rgma. | |
| SV2017005577A (es) | Metodos para diagnosticar y tratar el cancer | |
| EP3397150A4 (en) | SYSTEM AND METHOD FOR NEUROLOGICAL MONITORING AND SUPPORTED DIAGNOSIS | |
| IL253860B (en) | Devices for biological sample collection and analysis and methods of use thereof | |
| PL3482209T3 (pl) | Oznaczenie do wykrywania alfa-synukleiny i sposób diagnozowania alfa-synukleinopatii | |
| GB201712299D0 (en) | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results | |
| EP3825683C0 (en) | SYSTEM AND METHOD FOR DETECTING ANALYTES IN PHYSIOLOGICAL GAS SAMPLES | |
| EP3307142A4 (en) | DEVICE AND METHOD FOR EXAMINING SKIN Lions | |
| MX387936B (es) | Metodo para la cuantificacion de huevos de parasitos en las heces. | |
| MX2016002423A (es) | Composiciones y metodos de diagnostico para el tratamiento de glioblastoma. | |
| EP2849431A4 (en) | METHOD AND DEVICE FOR DETECTING BACKLIGHTING | |
| PL3523639T3 (pl) | Odczynniki wykrywające i układy elektrod do elementów diagnostycznych testów wieloanalitowych oraz sposoby ich zastosowania | |
| EP3274619C0 (en) | APPARATUS AND METHOD FOR DETECTING AND MONITORING THE CONDITION OF PIPELINE COMPONENTS | |
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| FR3029288B1 (fr) | Procede de detection et de caracterisation par ultrasons de defauts dans un materiau heterogene | |
| EP2982971A4 (en) | DEVICE DETECTION METHOD BY ULTRASOUND AND DEVICE DETECTION DEVICE BY MEANS OF ULTRASOUND | |
| EP3374524A4 (en) | PROCESS FOR DETECTION OF 5-HYDROXYMETHYLCYTOSINE AND FOR DIAGNOSIS OF CANCER | |
| MX2022010954A (es) | Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo. | |
| WO2015042326A3 (en) | Methods for detection and treatment of neurodegenerative diseases | |
| EA201700208A1 (ru) | Способ и устройство для обнаружения малярии | |
| HUE056738T2 (hu) | Eljárás gyógyszer elleni antitestek, különösen kezelés kapcsán kialakuló gyógyszer elleni antitestek detektálására és/vagy mérésére | |
| EP3561507A4 (en) | DIAGNOSIS DEVICE USING SALIVA AND CORRESPONDING DIAGNOSIS METHOD | |
| BR112016028838A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer | |
| SG10201901836PA (en) | Test strip assembly | |
| MX384485B (es) | Deteccion temprana de preeclampsia. |